-
公开(公告)号：EP1251738B1
公开(公告)日：2008-12-17
申请号：EP01905454.3
申请日：2001-02-05
申请人： Theracos, Inc.
IPC分类号： A01N37/10 , C07C233/54 , C07C59/64
CPC分类号： C07C43/23 , C07C59/64 , C07C233/54
摘要： Novel diphenylethylene compounds that are administered orally to decrease circulating concentrations of glucose are provided. The effect on insulin resistant rats is also shown. The effects on lipid and leptin concentrations are also shown. The compounds are orally effective anti-diabetic agents that may normalize glucose and lipid metabolism in subjects with diabetes.
-
公开(公告)号：EP1549625A1
公开(公告)日：2005-07-06
申请号：EP03774638.5
申请日：2003-10-08
申请人： Theracos, Inc.
IPC分类号： C07D277/34 , C07D277/20 , A61K31/426 , A61P3/10
CPC分类号： C07D277/20 , C07D277/24 , C07D277/34
摘要： Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.
摘要翻译： 提供了含有噻唑烷二酮或恶唑烷二酮部分的新型二苯基乙烯化合物及其衍生物，其可有效降低II型糖尿病动物模型中的血糖水平，血清胰岛素，甘油三酯和游离脂肪酸水平。 公开的化合物可用于多种治疗，包括治疗炎症，炎性和免疫性疾病，胰岛素抵抗，高脂血症，冠状动脉疾病，癌症和多发性硬化症。
-
3.发明公开
公开(公告)号：EP1448515A2
公开(公告)日：2004-08-25
申请号：EP02804467.5
申请日：2002-11-27
申请人： Theracos, Inc.
发明人： NEOGI, Partha , DEY, Debendranath , LI, Ta-Kai , FULLER, Joseph , CHEN, Liang
IPC分类号： C07C235/34 , C07C235/28 , C07C237/22 , C07C271/16 , C07C271/64 , C07C275/50 , C07C281/06 , C07C317/22 , C07C335/26 , C07D213/56 , C07D213/643 , C07D213/75 , C07D295/182 , C07D317/60 , A61K31/16 , A61K31/17 , A61K31/175 , A61K31/19 , A61K31/216 , A61K31/27 , A61K31/36
CPC分类号： C07D213/643 , C07C233/25 , C07C235/34 , C07C235/56 , C07C237/22 , C07C271/16 , C07C271/64 , C07C275/50 , C07C281/06 , C07C317/22 , C07C2601/14 , C07D213/56 , C07D213/75 , C07D295/185
摘要： Novel acyl urea, thiourea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction, in an animal model of arthritis and in lowering blood glucose levels in animal models of Type II diabetes mellitus. The compounds are disclosed as useful for a variety of treatments including the treatment of diabetes mellitus, insulin resistance, inflammation, inflammatory diseases, immunological diseases and cancer.
摘要翻译： 提供新颖的酰基脲，硫脲，氨基甲酸酯，硫代氨基甲酸酯和相关化合物是能有效地抑制在培养的细胞中的细胞因子介导的炎症反应，在改善的骨破坏，在关节炎的动物模型中和在动物模型中降低血糖水平 II型糖尿病。 这些化合物游离缺失盘用于各种治疗，包括糖尿病，胰岛素抵抗，炎症，炎性疾病，免疫性疾病和癌症的治疗中是有用的。
-
公开(公告)号：EP1360178B1
公开(公告)日：2009-02-18
申请号：EP01944241.7
申请日：2001-06-05
申请人： Theracos, Inc.
IPC分类号： A61K31/426 , C07D277/34
CPC分类号： C07D277/20 , C07D277/24 , C07D277/34
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
